TRDA
Entrada Therapeutics, Inc.
NASDAQHealthcareBiotechnologyUS
Rating:C+
Company Profile
CEO
Dipal Doshi
IPO Date
2021-10-29
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Entrada Therapeutics, Inc.
CEO
Dipal Doshi
IPO Date
2021-10-29
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 19,000 |
| $5.97 |
| 12 Jun 2026 | Zeiher Bernhardt G | director | A-Award | Acquired | 19,000 | $5.97 |
| 12 Jun 2026 | PARMAR KUSH | director, 10 percent owner: | A-Award | Acquired | 19,000 | $5.97 |
| 12 Jun 2026 | KIM PETER S | director | A-Award | Acquired | 19,000 | $5.97 |
| 12 Jun 2026 | Chapman Gina | director | A-Award | Acquired | 19,000 | $5.97 |
| 21 May 2026 | Zeiher Bernhardt G | director | P-Purchase | Acquired | 5,000 | $5.86 |
| 4 May 2026 | Sethuraman Natarajan | President, Research & Develop. | S-Sale | Disposed | 25,907 | $15.39 |
| 4 May 2026 | Dowden Nathan J | President & COO | M-Exempt | Acquired | 15,000 | $1.74 |
| 4 May 2026 | Dowden Nathan J | President & COO | S-Sale | Disposed | 15,000 | $15.33 |